Viridian Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.8M | $302.0K | $314.0K | $1.8M | $3.0M | $1.1M | $4.5M | $8.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | $34.8M | $30.4M |
| SG&A Expense | $95.3M | $61.1M | $95.0M | $35.2M | $25.8M | $13.3M | $11.6M | $11.0M |
| Operating Income | $-363.4M | $-299.0M | $-254.5M | $-134.3M | $-79.7M | $-110.4M | $-42.0M | $-33.1M |
| Operating Margin | -512.9% | -99,018.2% | -81,035.0% | -7,579.2% | -2,690.8% | -10,512.4% | -941.0% | -394.5% |
| Interest Expense | — | — | — | $500.0K | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | — | — | — | — | — | — |
| Net Income | $-342.6M | $-269.9M | $-237.7M | $-129.9M | $-79.4M | $-110.7M | $-41.9M | $-32.7M |
| Net Margin | -483.6% | -89,387.1% | -75,711.5% | -7,329.2% | -2,680.2% | -10,544.3% | -938.6% | -390.0% |
| EPS (Basic) | — | — | $-5.31 | $-4.05 | $-6.66 | $-10.38 | $-6.68 | $-0.37 |
| EPS (Diluted) | — | — | $-5.31 | $-4.05 | $-6.66 | $-10.38 | $-6.68 | $-0.37 |
| Shares Outstanding (Basic) | 101.8M | 81.0M | 44.8M | 32.1M | 11.9M | 10.7M | 7.0M | 92.5M |
| Shares Outstanding (Diluted) | 101.8M | 81.0M | 44.8M | 32.1M | 11.9M | 10.7M | 7.0M | 92.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |